[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.168.204. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 809
Citations 0
Letters
February 27, 2013

Antiviral Therapy and Hepatitis B Virus–Related Hepatocellular Carcinoma Recurrence

Author Affiliations
 

Letters Section Editor: Jody W. Zylke, MD, Senior Editor.

Author Affiliations: Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan (Ms Yeh and Dr Lai) (mslai@cph.ntu.edu.tw); and Hepatitis Research Center, National Taiwan University and Hospital, Taipei, Taiwan (Dr Chen).

JAMA. 2013;309(8):765-767. doi:10.1001/jama.2013.571

To the Editor: Nucleoside analogues are an effective treatment against HBV infection. However, previous studies have yielded inconclusive results regarding a reduction in the risk of HCC recurrence following the use of these treatments due to the small number of patients. Using a nationwide cohort, Dr Wu and colleagues1 reported survival benefits for patients treated with nucleoside analogues. We have 2 comments to make regarding their findings.

First Page Preview View Large
First page PDF preview
First page PDF preview
×